StockNews.com downgraded shares of Seres Therapeutics (NASDAQ:MCRB - Free Report) from a hold rating to a sell rating in a research report report published on Saturday.
A number of other brokerages have also weighed in on MCRB. JPMorgan Chase & Co. lowered Seres Therapeutics from a "neutral" rating to an "underweight" rating in a research note on Thursday, October 24th. Chardan Capital restated a "buy" rating and issued a $1.25 price objective on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $10.00 target price on shares of Seres Therapeutics in a research report on Thursday, November 14th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $5.08.
Check Out Our Latest Stock Report on MCRB
Seres Therapeutics Price Performance
MCRB opened at $0.84 on Friday. The firm has a market capitalization of $144.15 million, a P/E ratio of -3.67 and a beta of 2.13. Seres Therapeutics has a one year low of $0.54 and a one year high of $1.53. The company has a fifty day moving average price of $0.83 and a 200-day moving average price of $0.90.
Institutional Trading of Seres Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of Seres Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company's stock worth $21,625,000 after acquiring an additional 140,096 shares during the last quarter. Geode Capital Management LLC boosted its position in Seres Therapeutics by 22.5% during the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company's stock valued at $1,314,000 after buying an additional 255,014 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Seres Therapeutics by 42.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company's stock valued at $708,000 after buying an additional 222,771 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in shares of Seres Therapeutics in the third quarter worth about $374,000. Finally, State Street Corp lifted its stake in shares of Seres Therapeutics by 12.9% in the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock valued at $363,000 after acquiring an additional 43,700 shares during the last quarter. Hedge funds and other institutional investors own 59.34% of the company's stock.
About Seres Therapeutics
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
Recommended Stories
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
